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t 2   Abbreviations: 
HNSCC: head and neck squamous cell carcinoma 
FFQ: food frequency questionnaire 
GI: glycemic index 
GL: glycemic load 
UM HN-SPORE: University of Michigan Head and Neck Specialized Program of Research 
Excellence 
BMI: body mass index 
HR: hazard ratio 
CI: confidence interval 
HPV: human papillomavirus 
ROS: reactive oxygen species 
 
 
Article Category: Cancer Epidemiology 
 
 
Novelty and Impact: As interest in the potential for “sugar” to impact cancer progression 
increases, we investigated how carbohydrate intake is associated with head and neck cancer 
outcomes in a prospective cohort of newly diagnosed patients. Higher pretreatment intakes of 
total carbohydrate, total sugar, glycemic load, and simple carbohydrate foods were significantly 
associated with increased risk of mortality. Associations differed by tumor site and cancer stage. 
Randomized controlled trials testing the impact of dietary carbohydrate restriction on head and 
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t 3  ABSTRACT 
No studies have evaluated associations between carbohydrate intake and head and neck 
squamous cell carcinoma (HNSCC) prognosis. We prospectively examined associations between 
pre- and post-treatment carbohydrate intake and recurrence, all-cause mortality, and HNSCC- 
specific mortality in a cohort of 414 newly diagnosed HNSCC patients. All participants 
completed pre- and post-treatment Food Frequency Questionnaires (FFQs) and epidemiologic 
surveys. Recurrence and mortality events were collected annually. Multivariable Cox 
Proportional Hazards models tested associations between carbohydrate intake (categorized into 
low, medium and high intake) and time to recurrence and mortality, adjusting for relevant 
covariates. During the study period, there were 70 deaths and 72 recurrences. In pretreatment 
analyses, high intakes of total carbohydrate (HR: 2.29; 95% CI: 1.23 – 4.25), total sugar (HR: 
3.03; 95% CI: 1.12 – 3.68), glycemic load (HR: 2.10; 95% CI: 1.15, 3.83), and simple 
carbohydrates (HR 2.26; 95% CI 1.19 – 4.32) were associated with significantly increased risk of 
all-cause mortality compared to low intake. High intakes of carbohydrate (HR 2.45 (1.23 – 4.25) 
and total sugar (HR 3.03; 95% CI 1.12 – 3.68) were associated with increased risk of HNSCC-
specific mortality. In post-treatment analyses, medium fat intake was significantly associated 
with reduced risk of recurrence (HR 0.08; 95% CI 0.01 – 0.69) and all-cause mortality (HR 0.27; 
95% CI 0.07 – 0.96). Stratification by tumor site and cancer stage in pretreatment analyses 
suggested effect modification by these factors. Our data suggest high pretreatment carbohydrate 
intake may be associated with adverse prognosis in HNSCC patients. Clinical intervention trials 
to further examine this hypothesis are warranted.  
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t 4   
INTRODUCTION 
Despite advances in our understanding of the biology of HNSCC, 5-year survival rates of 
this disease have remained low (~65%) likely attributable to late detection and high rates of 
persistent and recurrent disease (1, 2). Previous research has suggested that a dietary pattern 
characterized by high intakes of vegetables and fruits (3) and having high pretreatment serum 
carotenoid levels (4) are associated with more favorable HNSCC prognoses. In addition to 
dietary patterns and serum carotenoids, it may also be informative to investigate the associations 
of other aspects of diet with these outcomes in the HNSCC population. To our knowledge, 
macronutrient composition, carbohydrate in particular, has not yet been examined in relation to 
HNSCC prognosis. 
The role of carbohydrate intake in cancer development and prognosis has recently 
become an area of interest due to a resurgence of attention on the “Warburg effect,” the view that 
cancer cells metabolize glucose exclusively as a fuel, using aerobic glycolytic metabolism.(5) 
This inefficient process produces less ATP per mole of glucose than does oxidative 
phosphorylation.(6, 7)  As a result, cancer cells require high amounts of glucose to engage in 
mitosis and continued proliferation. The evolution of this unique metabolism may have resulted 
from mitochondrial damage, a universal characteristic of cancer cells that potentially renders 
them dependent upon glycolysis for energy production.(8)  It has also been speculated that the 
rapid proliferation of cancer cells led to dependence upon a fuel that could double as a source of 
carbon for building the infrastructure of daughter cells.(6)  Regardless of its origin, the 
dependence of cancer cells on glycolysis may make them exquisitely sensitive to an 
endocrine/metabolic environment that deprives them of glucose.  
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t 5  One potential and feasible means of creating an internal milieu that may be incompatible 
with cancer is to restrict dietary carbohydrates. Restriction of sugar and carbohydrate-containing 
foods not only stabilizes or lowers blood glucose, but also reduces circulating insulin.  Because 
insulin facilitates glucose uptake by cancer cells, the decline in insulin may further deprive 
cancer cells of their sole source of fuel, leading to improved prognosis.(9)  Herein, we examined 
associations between pre- and post-treatment total carbohydrate intake and recurrence, all-cause 
mortality, and HNSCC-specific mortality in a well-characterized, prospective cohort of newly 
diagnosed, previously untreated HNSCC patients. To our knowledge, this is the first 
epidemiological study to assess carbohydrate intake in relation to outcomes after HNSCC 
diagnosis. Our hypothesis was that we would observe higher rates of recurrence and mortality in 
HNSCC patients who reported consuming a diet high in total carbohydrates. We also explored 
other indices of carbohydrate intake for comparison, including total sugar, added sugar, natural 
sugar, glycemic index (GI),  glycemic load (GL), starchy foods, and simple carbohydrate foods, 
as well as total protein and total fat intake. 
SUBJECTS AND METHODS 
Study population 
This prospective cohort study used data collected as part of the University of Michigan 
Head and Neck Specialized Program of Research Excellence (UM HN-SPORE). From 
November, 2008 to August, 2012, the HN-SPORE study staff approached every newly-
diagnosed, previously untreated HNSCC patient that presented at UM hospital clinics to 
participate. Subjects were screened for eligibility, with exclusion criteria including: 1) <18 years 
of age; 2) pregnant; 3) non-English speaking; 4) diagnosed as mentally unstable; 5) diagnosed 
with another non-upper aerodigestive tract cancer; or 6) diagnosed with any other primary 
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t 6  HNSCC within the past five years. During the recruitment period, N=520 provided written, 
informed consent for a response rate of 92%. Study activities were approved by the Institutional 
Review Board of the University of Michigan Medical School and carried out in accordance with 
the Helsinki Declaration of 1975 as revised in 1983. 
Consenting participants were asked to complete a detailed health behaviors survey upon 
entrance into the study and annually that collected data on demographics, epidemiologic 
characteristics and health behaviors. A medical chart review was conducted on each participant 
at baseline and updated annually to collect data on clinical variables including tumor site and 
stage, comorbidities, treatment modalities, recurrence and survival status. Dietary data were 
obtained at baseline and one year after diagnosis using the self-administered 2007 Harvard 
FFQ.(10) Of the original 520 eligible participants, N=440 (84.6%) completed the baseline 
(pretreatment) FFQ and N=303 (58.3%) completed the 1-year (post-treatment) FFQ. Participants 
were excluded from analysis if they had left complete pages missing on the FFQ (N=17 for 
pretreatment and N=24 for post-treatment), had more than 70 missing items on the FFQ (N=1 for 
pretreatment and N=4 for post-treatment) or reported a total energy intake >5000 kcals/day or 
<200 kcals/day (N=8 for pretreatment and N=10 for post-treatment). The final sample size was 
N=414 for pretreatment analysis and N=265 for post-treatment analysis. 
Measures 
Predictors: Carbohydrate, protein and fat intake 
The semi-quantitative 2007 Harvard FFQ was used to estimate participants’ usual pre- 
and post-treatment dietary intake of food, beverages and supplements over the past year. The 
reproducibility and validity of this FFQ has been previously reported (11-13). Briefly, the FFQ 
was evaluated for reproducibility and validity in a large prospective male cohort and a large 
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t 7  prospective female cohort separately. Study participants were administered the FFQ twice and 
completed four one-week diet records during a one year period. Correlation coefficients between 
energy-adjusted nutrients measured by diet records and the FFQ ranged from 0.28 – 0.86 and 
were reproducible from the first FFQ administration to the second.  Indices of carbohydrate 
intake included total carbohydrate (g/day); glycemic index and load; and total, added, and natural 
sugar (g/day), fructose (g/day), starches (servings/day), and simple carbohydrates (servings/day). 
The nutrient database used to calculate nutrient intakes was developed by investigators at the 
Harvard T.H. Chan School of Public Health. Total sugar was defined as the sum of sucrose, 
fructose, lactose, glucose and maltose. Added sugar was added to the Harvard nutrient database 
in May 2009 using data from the USDA added sugar database (14). Natural sugar was defined as 
total sugar minus added sugar. For the purpose of this analysis, starchy foods were defined as the 
number of servings per day of whole grains, potatoes, legumes, and other vegetables combined. 
Simple carbohydrate foods were defined as the number of servings per day of refined grains, 
desserts, and sugar sweetened beverages combined.  Total protein and total fat intake (g/day) 
were examined individually. All nutrient variables were categorized into tertiles (high, medium, 
low) to maintain statistical power and for ease of interpretability. 
Covariates 
 Demographic variables included age, sex and race. Body mass index (BMI; kg/m
2
) at the 
time of diagnosis was calculated based on self-reported height and weight measures, which were 
previously reported to be well correlated (r = 0.98) with clinically measured height and weight in 
this patient population (3).  Percent weight change in the year after diagnosis, also based on self-
report, was categorized as gain or <2% loss, 2-10% loss and >10% loss. Tobacco use and alcohol 
consumption data were categorized as current, former or never, where “current” status reflects 
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t 8  use in the 12 months prior to cancer diagnosis. Disease site categories included oral cavity (N = 
152), oropharynx (N=166), hypopharynx (N=10) and larynx (N= 86). Clinical stage was 
categorized into two groups, stage I/II and stage III/IV. As previously described, an ultrasensitive 
method determined human papillomavirus (HPV)-status of the tumor was categorized as positive 
(N=80), negative (N=117), or unknown (N=217). Depressive symptoms (yes or no) were 
assessed using the 5-item Geriatric Depression Scale-Short Forms (15). Comorbidities were 
recorded according to the Adult Comorbidity Evaluation-27 instrument and categorized into 
none or mild versus moderate to severe comorbidities (16).  
Outcomes 
Recurrence and overall mortality 
 Study participants were followed longitudinally in accordance with the National 
Comprehensive Cancer Network guideline intervals. New tumor events and status, including 
recurrence, residual disease, persistent disease and second primary cancers were updated at each 
visit to UM clinics and annually via medical record review. Information on tumor events and 
status of participants who did not return to UM for surveillance after completing treatment was 
collected through self-report and contact with local physicians. Deaths were captured through the 
Social Security Death Index, yearly survey updates, notification from family or medical record 
reviews. When possible, cause of death was recorded. Survival time and recurrence/persistence-
free time for pre-treatment analyses were calculated beginning at date of diagnosis. Survival time 
was censored to February 1, 2014 and recurrence-free time was censored to the last date of each 
participant’s annual medical record review. Participants with persistent disease were assigned a 
recurrence-free time of one day. Participants lost to follow-up were censored to their date of last 
known status. To avoid immortal time bias in post-treatment analyses, survival and recurrence 
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t 9  time were calculated beginning at the date the post-treatment FFQ was administered until the 
date of event or censoring. N = 66 participants who experienced a recurrence event prior to the 
date of the post-treatment FFQ were excluded from post-treatment recurrence analyses.  
Statistical Analysis 
 Descriptive statistics (means and frequencies) were generated for all demographic, clinic-
pathologic and epidemiological characteristics and nutrient intakes. Univariate analyses were 
conducted to test for differences in intakes of nutrient variables of interest by demographic, 
clinic-pathologic and epidemiologic characteristics. All nutrient variables of interest were energy 
adjusted using the residual method. Survival time and recurrence/persistence-free time were 
calculated beginning at date of diagnosis.  
 Multivariable Cox proportional hazard models were built to estimate hazard ratios (HRs) 
and 95% confidence intervals (CIs) for the associations between each nutrient and recurrence, 
all-cause mortality, and HNSCC-specific mortality after adjusting for other prognostic factors 
that were selected for consideration a priori. All final multivariable models for pretreatment 
analysis included age, stage, tumor site, HPV-status, smoking, total fruit and vegetable intake, 
and total caloric intake.  Final multivariable models for post-treatment analysis included the 
same variables with the addition of percent weight change. Covariates were chosen based on a 
priori knowledge of variables associated with head and neck cancer survival. Treatment 
modality was considered as a covariate, but ultimately excluded from final models because it is 
significantly correlated with tumor site (Spearman r = 0.42, p < 0.001). HRs and 95% CIs were 
estimated for each tertile (medium and high intakes) compared with tertile 1 (low intake). A test 
for trend across increasing tertiles of intake was performed by setting each individual’s nutrient 
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t 10  value to the median for that tertile and treating it as a continuous variable in Cox regression 
models. 
 To assess potential effect modification by tumor site and disease stage, significant 
pretreatment associations were examined for the two most common sites, oral cavity and 
oropharynx separately, as well as for stages 1-3 and stage 4 separately.  The study sample lacked 
the statistical power to examine HNSCC-specific survival stratified by tumor site or for post-
treatment analyses. All statistical analyses were performed in SAS 9.4 (SAS Institute Inc., Cary, 
NC). P values < 0.05 were considered statistically significant. No multiplicity adjustments were 
performed. 
RESULTS 
 During the longitudinal follow-up period, there were 72 recurrence events (17.4%), 70 
death events from any cause (16.9%), 42 death events from HNSCC (10.1%), and median 
follow-up time of 26 months. Demographic, behavioral and clinical characteristics of the study 
population are displayed in Table 1. The mean age at diagnosis was 60.9 years old with a range 
of 25 – 95. About one quarter (24%) of participants were female and the majority (94.9%) were 
non-Hispanic white. Nearly 65% of participants were classified as overweight or obese at the 
time of diagnosis, a slightly higher proportion than the 60% observed in our previous HNSCC 
cohort.(3) ~69% of the study population experienced ≥ 2% weight loss in the year following 
diagnosis. Most commonly diagnosed tumors were oropharynx (40.1) and stage III or IV 
(69.1%). Among participants with known tumor HPV-status (including all sites), 40.6% were 
positive. Depressive symptoms were reported among 40.5% of participants and ~25% were 
considered to have moderate to severe comorbidities. 72.2% of participants were current or 
former smokers and 92.8% reported current or former alcohol consumption.  
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t 11   Distributions of pretreatment and post-treatment intake of dietary variables are displayed 
in Supplementary Table 1. Select characteristics of the study participants, according to tertiles 
of pretreatment intake (low, medium and high) are shown in Table 2. Current drinkers were 
more likely to be in the low categories for carbohydrate, total sugar, added sugar and glycemic 
load. Females were significantly more likely to report in the high carbohydrate and low glycemic 
index categories compared to males. Mean age decreased across increasing categories of 
glycemic index. A smaller proportion of participants in the low added sugar category had ≤ a 
high school education and depressive symptoms.  
 Pretreatment results of multivariable time-to-event Cox proportional hazards analysis for 
recurrence, all-cause mortality, and HNSCC-specific survival are shown in Table 3. Unadjusted 
results for both pretreatment and post-treatment analyses are shown in Supplemental Table 2. 
Post-treatment results of multivariable time-to-event Cox proportional hazards models for 
recurrence and overall survival are displayed in Supplemental Table 3. There was a significant 
trend towards increased all-cause mortality with increasing pretreatment total carbohydrate 
intake, total sugar, glycemic load, and simple carbohydrate foods. A similar trend was observed 
for pretreatment total carbohydrate and total sugar intake with recurrence, but the HRs were 
smaller and did not reach statistical significance. Compared to low intake, high pretreatment 
intake of starchy foods was associated with reduced risk of all-cause mortality, HNSCC-specific 
mortality and recurrence. High intakes of carbohydrate and total sugar were significantly 
associated with increased risk of HNSCC-specific mortality compared to low. No other dietary 
variables assessed in pretreatment analyses were significantly associated with mortality or 
recurrence.  
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t 12  No dietary variables assessed in post-treatment analyses were significantly associated 
with mortality or recurrence and thus results are displayed in Supplemental Table 3. The 
exception was that compared to Low intake, Medium post-treatment intake of total fat was 
significantly associated with a reduction in risk of both mortality (HR 0.27; 95% CI 0.07 – 0.96) 
and recurrence (HR 0.08; 95% CI 0.01 – 0.69).  
Results of pretreatment subanalyses that stratified by tumor site and cancer stage for 
significant variables are displayed in Table 4. Interestingly, statistically significant associations 
remained for oral cavity cancers but not for oropharyngeal cancers. Similarly, significant 
associations remained for stage 1-3 cancers but not stage 4 cancers. The exception was for total 
sugar, which was not statistically significant for stage 1-3 cases, but was significant for stage 4 
cases.   
DISCUSSION 
 In this prospective cohort study of newly diagnosed, previously untreated HNSCC 
patients, we found that high pretreatment intakes of carbohydrate, total sugar, glycemic load, and 
simple carbohydrate foods were significantly associated with increased risk of all-cause 
mortality after adjusting for other known prognostic variables. Significant associations remained 
for pretreatment intakes of carbohydrate and total sugar when examining these variables in 
relation to HNSCC-specific mortality. Stratified analyses of statistically significant associations 
suggest potential effect modification by tumor site and cancer stage. In post-treatment analysis, 
medium fat intake was significantly associated with a greater reduction in risk for both mortality 
and recurrence. To our knowledge this is the first study to prospectively examine associations 
between carbohydrate intake and HNSCC recurrence and mortality.  
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t 13  In this study, intakes of carbohydrate and fat were independently associated with cancer 
outcomes.  Looking across both phases (pre- and post-treatment), higher intakes of carbohydrate, 
total sugar, glycemic load, and simple carbohydrate foods were variably associated with greater 
recurrence and mortality, whereas post-treatment medium fat intake was associated with lower 
recurrence and mortality.  These observations suggest that both restriction of dietary 
carbohydrate and a moderate increase in dietary fat may have independent effects, and suggest 
that overall macronutrient composition, rather than foods or macronutrients individually, may be 
relevant in determining cancer outcomes.  The theoretical basis through which alteration in 
dietary carbohydrate or fat intake could affect cancer-related outcomes has been reviewed.(6, 9)  
In general, higher dietary carbohydrate could provide the glucose necessary to support 
metabolism of cancer cells, which are obligately glycolytic. Higher carbohydrate intake also 
stimulates insulin secretion, which not only accelerates glucose uptake by cancer cells, but also 
stimulates mitogenesis.  Higher fat intake could impair metabolism of cancer cells, which cannot 
use fat as a fuel, and would increase production of ketones, which appear to interfere with cancer 
cell glycolysis.(7, 9)   
Based on these concepts, in previous studies, a carbohydrate-restricted (ketogenic) diet 
was developed and tested in cancer patients and model systems.(17-20)  Preclinical data support 
the ability of a low carbohydrate, ketogenic diet to improve survival and decrease tumor burden. 
In a mouse model of astrocytoma, the ketogenic diet increased apoptosis, inhibited angiogenesis, 
and extended survival.(21-24)  In a mouse model of malignant glioma, consumption of a 
ketogenic diet slowed tumor growth, prevented increases in reactive oxygen species (ROS) 
associated with tumor growth, and shifted gene expression patterns in tumor tissue to more 
closely resemble those of healthy tissue.(25)  These results suggest that reduced production of 
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t 14  ROS in the tumor may limit growth and angiogenesis, processes that depend upon ROS 
signaling, while at the same time, promote apoptosis. The effect of the diet on gene expression in 
both healthy and cancerous brain tissue suggests that the anti-cancer effects of the ketogenic diet 
are far more extensive than simply lowering glucose. 
While our data supports a potential benefit to HNSCC patients avoiding higher levels of 
carbohydrate intake, it cannot be used to draw conclusions related to the benefits of a ketogenic 
diet. In our study population the median for the low carbohydrate group was 199 g/day for 
pretreatment intake and 189g/day for post-treatment intake—much higher than what is 
considered ketogenic (≤20 g/day). However, there may be biological plausibility for benefits of 
the ketogenic diet in HNSCC patients in particular, since HNSCC is a highly glycolytic form of 
cancer.(9) The therapeutic potential of the ketogenic diet for this population has recently been 
reviewed.(9) In theory, the high fat (energy) content of the ketogenic would help preserve lean 
muscle mass in patients who have difficulty eating.(26-28)  At the same time, the combination of 
medium fat and low sugar/carbohydrate would minimize fuel availability to the cancer cells, 
which are highly dependent upon glucose, and potentially inhibit cancer cell growth. While the 
optimal amount of carbohydrate intake requires further exploration, our results may be the first 
observational data in humans to support the therapeutic potential of a diet characterized by 
carbohydrate restriction and elevated fat intake within a population of HNSCC patients.   
Associations of all post-treatment dietary variables, with the exception of medium fat 
intake, were null. This could be due to a lack of statistical power as a result of shorter follow-up 
time, smaller sample size, and fewer recurrence and mortality events. Another possible 
explanation is that dietary intake of carbohydrates has the greatest effect on outcomes prior to or 
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t 15  during active oncological treatment. Further research should assess how timing of carbohydrate 
intake across the cancer continuum influences cancer outcomes. 
In stratified analyses of statistically significant pretreatment dietary variables, there was a 
suggestion of effect modification by tumor site and cancer stage. Specifically, high intake of total 
carbohydrate, total sugar, glycemic load, and simple carbohydrate foods were significantly 
associated with increased risk of all-cause mortality in oral cavity cancer cases but not in 
oropharyngeal cases. In stratified analyses by stage, high carbohydrate and glycemic load was 
significantly associated with increased risk of all-cause mortality in stage 1-3 cancers but not 
stage 4. High total sugar intake was significantly associated with higher mortality in stage 4 
cancers but not stage 1-3. An explanation for these results is unclear; since the majority of oral 
cavity cancers are diagnosed in earlier stages, and the opposite is true for oropharyngeal cancers, 
it is possible that carbohydrate intake has a greater effect on the progression of earlier stage 
cancers than on late stage cancers. Future studies should address potential differences of the 
effect of carbohydrate intake on HNSCC outcomes across different tumor site and cancer stages. 
Strengths of this analysis include the prospective, longitudinal design, the examination of 
both pre-and post-treatment dietary intake, uniform treatment regimens, the ability to investigate 
both all-cause mortality and HNSCC-specific mortality, and the adjustment for multiple 
prognostic variables, including HPV-status. Results of this analysis can be generalized to other 
predominately non-Hispanic White HNSCC patient populations but the generalizability to more 
diverse HNSCC populations is limited. 
Results do need to be considered cautiously in light of some limitations. Swallowing 
difficulties prior to and following treatment for head and neck cancers are common and could 
lead to dietary alterations favoring carbohydrate and sugar intake. This would be particularly true 
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t 16  for patients with advanced disease which comprised the majority of our cohort. Radiation 
therapy which is commonly used for oropharyngeal cancer treatment and as part of 
multimodality treatment for patients with advanced disease also significantly affects swallowing 
function. Additionally, it is likely a large number of patients in the study population received 
nutrition support in the form of liquid oral or enteral nutrition during the study period but this 
was not well captured by the FFQ and thus we were not able to separately analyze for liquid 
nutritional supplementation in this analysis. Although results suggest reduction in risk of 
recurrence and mortality with medium post-treatment fat intake, the current study only 
investigated total fat. Future research should examine differences in association by subcategories 
of fat, including saturated, unsaturated, omega-3, and omega-6 fat intake. Also, the shorter 
follow-up time, smaller sample size, and decreased number of recurrence and survival events is a 
limitation of our post-treatment analyses. Finally, the FFQ is vulnerable to potential systematic 
biases and measurement error and the observational study design does not prove causality but 
merely an association between the predictors and outcomes.  
 In summary, this is the first epidemiologic study examining associations between 
carbohydrate intake and survival outcomes in HNSCC. Our findings suggest that high 
pretreatment intakes of total carbohydrate and total sugar may be associated with increased all-
cause mortality and HNSCC-specific mortality in HNSCC patients. These associations may be 
modified by tumor site and cancer stage. While these results need to be interpreted with caution, 
these data support the development of randomized controlled trials that test the effect of limiting 
carbohydrate intake and/or adjusting the macronutrient composition of HNSCC patients and the 
magnitude of restriction/control that optimally balances patient adherence, quality of life and 
cancer outcomes requires further study. Prior to developing new medical nutrition therapy 
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t 17  recommendations for HNSCC patients, translational dietary intervention research should be 
conducted to further elucidate the potential role of carbohydrate restriction and/or macronutrient 
composition on prognostic outcomes in this patient population.  
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Table 1. Patient clinical and epidemiologic characteristics (n=414) 
Characteristic Number (percent) 
Age [Mean (SD) and range] 60.9 (11),  25 - 95 
Female 99 (24.0) 
Non-Hispanic white 393 (94.9) 
All-Cause Death Events 70 (16.9) 
HNSCC-Specific Death Events 42 (10.1%) 
Recurrence Events 72 (17.4) 
Persistent Disease
a
 29 (7.0) 




     Underweight (<18.5) 16 (3.9) 
     Normal (18.5-24.9) 131 (31.6) 
     Overweight (25-29.9) 157 (37.9) 




     Gain or <2% loss 82 (30.9) 
     2-10% loss 85 (32.1) 
     >10% loss 98 (37.0) 
Disease Site 
     Oral Cavity 152 (36.7) 
     Oropharynx 166 (40.1) 
     Larynx 86 (20.8) 
     Hypopharynx 10 (2.4) 
Clinical Stage 
     Stage I 75 (18.1) 
     Stage II 53 (12.8) 
     Stage III 55 (13.3) 
     Stage IV 231 (55.8) 
Treatment  
    Surgery alone 111 (26.8) 
    Radiation alone 32 (7.7) 
    Surgery + radiation 33 (8.0) 
    Radiation + chemotherapy 178 (43.0) 
    Surgery + radiation + chemotherapy 40 (9.7) 
    Unknown 20 (4.8) 
HPV-Positive
c
 80 (40.6) 
Depressive Symptoms 168 (40.5) 
Comorbidities 
    None/Missing
d
 116 (28.0) 
    Mild 197 (47.6) 
    Moderate 69 (16.7) 
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t 22     Severe 32 (7.73) Tobacco Status 
     Never 115 (27.8) 
     Current (within 12 months) 155 (37.4) 
     Former  (quit > 12 months) 144 (34.8) 
Alcohol Use Status 
     Never/Missing 30 (7.2) 
     Current (within 12 months) 288 (69.6) 
     Former  (quit > 12 months) 96 (23.2) 
Daily Fruit & Vegetable Servings [Mean (SD) and 
range] 3.9 (2.1), 0.1 – 12.5 
a
Disease considered persistent if patient never deemed disease-free 
b
N=265; Calculated as [(weight at one year - weight at baseline) / weight at baseline]  
*100 
c
HPV-status available for n=197 participants 
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Table 2. Selected characteristics by pretreatment nutrient intake 
Mean age Female (%) 















Low 60.2 18.9 38.7 28.3 68.8 44.4 22.6 83.2 
Medium 61.8 21.0 31.4 27.1 73.9 41.2 30.4 68.8 
High 60.8 31.9 33.6 27.0 64.5 41.7 29.7 57.2 
P-value 0.49 0.03* 0.43 0.10 0.24 0.85 0.23 <0.0001* 
Total Sugar 
Low 60.1 21.2 33.6 27.8 71.7 41.5 27.0 80.3 
Medium 61.7 23.9 35.5 27.7 68.1 40.1 30.4 67.4 
High 61.0 26.8 34.6 26.9 67.4 45.7 25.4 61.6 
P-value 0.50 0.55 0.94 0.39 0.70 0.63 0.63 0.006* 
Added Sugar 
Low 62.8 22.9 21.2 26.9 68.1 35.6 31.4 86.4 
Medium 60.4 23.5 40.7 28.0 69.7 39.8 31.9 63.9 
High 61.7 25.2 40.7 27.6 64.7 51.4 25.2 59.7 
P-value 0.18 0.91 0.001* 0.32 0.70 0.04* 0.34 <0.0001* 
Natural Sugar 
Low 62.0 21.8 41.2 27.4 70.6 46.4 22.7 73.1 
Medium 61.3 23.7 34.2 27.3 67.2 40.9 33.1 71.2 
High 61.6 26.0 27.1 27.9 64.7 38.9 32.8 65.5 
P-value 0.90 0.75 0.07 0.71 0.62 0.50 0.01* 0.38 
Glycemic Index 
Low 62.5 31.4 35.0 27.7 67.4 40.3 27.7 61.3 
Medium 61.4 17.4 29.2 27.5 70.3 43.5 26.8 75.4 
High 58.9 23.2 39.4 27.2 69.6 43.4 28.3 72.5 
P-value 0.02* 0.02* 0.20 0.71 0.86 0.84 0.25 0.09 
Glycemic Load 
Low 61.8 24.8 38.0 27.8 68.8 44.4 22.6 75.2 
Medium 60.0 20.3 32.8 27.4 72.5 39.3 31.2 74.6 
High 60.9 26.7 32.8 27.3 65.9 43.7 29.0 59.4 
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P-value 0.43 0.43 0.59 0.76 0.50 0.65 0.28 0.02* 
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 time-to-event cox proportional hazards analysis for mortality and 
recurrence by pretreatment nutrient intake (n=414) 
All-Cause Mortality
 
 (70 Events) 
Low Medium High Ptrend 
Carbohydrate 1.0 1.79 (0.93, 3.45) 2.29 (1.23, 4.25)* 0.01* 
Total Sugar 1.0 1.13 (0.60, 2.14) 3.03 (1.12, 3.68)* 0.02* 
Added Sugar 1.0 1.17 (0.59, 2.31) 1.21 (0.61, 2.40)  0.60 
Natural Sugar 1.0 1.38 (0.66, 2.85) 1.66 (0.77, 3.60) 0.20 
Glycemic Index 1.0 1.13 (0.63, 2.13) 0.78 (0.42, 1.47) 0.43 
Glycemic Load 1.0 1.57 (0.81, 3.02)   2.10 (1.15, 3.83)* 0.01* 
Starchy Foods 1.0 0.69 (0.40, 1.19) 0.46 (0.25, 0.85)* 0.09 
Simple Carb Foods 1.0 1.94 (1.02, 3.72)* 2.26 (1.19, 4.32)* 0.02* 
Protein 1.0 0.87 (0.49, 1.54) 0.99 (0.53, 1.84) 0.96 
Fat 1.0 0.60 (0.33, 1.11) 0.67 (0.38, 1.20) 0.28 
HNSCC-Specific Mortality (42 Events) 
Carbohydrate 1.0 1.40 (0.58, 3.35) 2.45 (1.14, 5.27)* 0.01* 
Total Sugar 1.0 0.90 (0.38, 2.11) 2.07 (0.98, 4.37) 0.04* 
Added Sugar 1.0 1.02 (0.40, 2.59) 1.34 (0.55, 3.29) 0.51 
Natural Sugar 1.0 2.21 (0.81, 6.05) 2.39 (0.83, 6.90) 0.11 
Glycemic Index 1.0 1.12 (0.53, 2.36) 0.58 (0.25, 1.33) 0.18 
Glycemic Load 1.0 0.74 (0.32, 1.71) 1.32 (0.64, 2.71) 0.40 
Starchy Foods 1.0 0.75 (0.44, 1.30) 0.51 (0.28, 0.95)* 0.16 
Simple Carb Foods 1.0 1.77 (0.97, 3.26) 1.77 (0.95, 3.27) 0.20 
Protein 1.0 0.69 (0.31, 1.50) 1.14 (0.54, 2.43) 0.77 




Carbohydrate 1.0 1.04 (0.57, 1.91) 1.31 (0.74, 2.33) 0.27 
Total Sugar 1.0 1.04 (0.56, 1.92) 1.69 (0.95, 3.00) 0.07 
Added Sugar 1.0 1.40 (0.70, 2.82) 1.39 (0.69, 2.82) 0.38 
Natural Sugar 1.0 1.87 (0.91, 3.82) 1.40 (0.63, 3.11) 0.39 
Glycemic Index 1.0 1.33 (0.75, 2.34) 0.81 (0.43, 1.52) 0.48 
Glycemic Load 1.0 0.73 (0.39, 1.36) 1.11 (0.64, 1.92) 0.73 
Starchy Foods 1.0 0.75 (0.44, 1.30) 0.51 (0.28, 0.95)* 0.16 
Simple Carb Foods 1.0 1.77 (0.97, 3.26) 1.77 (0.95, 3.27) 0.20 
Protein 1.0 0.75 (0.41, 1.35) 1.18 (0.66, 2.13) 0.63 
Fat 1.0 0.97 (0.52, 1.79) 1.13 (0.63, 2.01) 0.45 
a
Adjusted for age, tumor site, cancer stage, smoking, total fruit and vegetable intake, HPV-status and total caloric 
intake 
*Indicates significance at p<0.05 
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Table 4. Multivariable time-to-event cox proportional hazards analysis for all-cause mortality 
by pretreatment dietary intake and stratified by disease site
a
 and cancer stage
b
 
Oral Cavity (N=152) 
Low Medium High Ptrend 
Carbohydrate 1.0 2.89 (1.02, 8.17)* 3.04 (1.12, 8.26)* 0.03* 
Total Sugar 1.0 1.23 (0.46, 3.28) 3.14 (1.21, 8.10)* 0.02* 
Glycemic Load 1.0 2.60 (0.84, 8.00) 3.38 (1.31, 8.72)* 0.01* 
Starchy Foods 1.0 1.30 (0.54, 3.14) 0.71 (0.23, 2.19) 0.56 
Simple Carb Foods 1.0 3.20 (1.11, 9.27)* 3.91 (1.34, 11.39)* 0.01* 
Oropharynx (N=166) 
Carbohydrate 1.0 1.04 (0.28, 3.80) 1.69 (0.44, 6.49) 0.41 
Total Sugar 1.0 0.71 (0.22, 2.26) 1.22 (0.39, 3.76) 0.70 
Glycemic Load 1.0 1.67 (0.47, 5.95) 1.39 (0.35, 5.47) 0.72 
Starchy Foods 1.0 0.38 (0.11, 1.25) 0.56 (0.15, 2.12) 0.35 
Simple Carb Foods 1.0 1.92 (0.56, 6.51) 1.47 (0.35, 6.17) 0.76 
Stage 1-3 (N = 183) 
Carbohydrate 1.0 4.06 (0.98, 16.81) 5.11 (1.33, 19.68)* 0.02* 
Total Sugar 1.0 0.37 (0.10, 1.35) 1.80 (0.60, 5.41) 0.18 
Glycemic Load 1.0 5.44 (0.98, 30.24) 7.00 (1.51, 32.48)* 0.01* 
Starchy Foods 1.0 1.29 (0.44, 3.75) 0.89 (0.23, 3.45) 0.90 
Simple Carb Foods 1.0 1.63 (0.43, 6.23) 1.18 (0.33, 4.19) 0.99 
Stage 4 (N=231) 
Carbohydrate 1.0 1.38 (0.64, 3.00) 1.86 (0.88, 3.92) 0.10 
Total Sugar 1.0 1.35 (0.62, 2.93) 2.27 (1.06, 4.88)* 0.03* 
Glycemic Load 1.0 1.36 (0.63, 2.95) 1.62 (0.77, 3.38) 0.20 
Starchy Foods 1.0 0.77 (0.38, 1.58) 0.43 (0.17, 1.11) 0.08 
Simple Carb Foods 1.0 2.03 (0.94, 4.36) 2.06 (0.91, 4.67) 0.10 
a
Adjusted for age, cancer stage, smoking, total fruit and vegetable intake, hpv, and total caloric intake 
b
Adjusted for age, tumor site, smoking, total fruit and vegetable intake, hpv, and total caloric intake 
*Indicates significance at p<0.05 
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t 27 Supplementary Table 1. Estimated median reported nutrient intakes by tertile 
 Pre-treatment (n=414) 
 Low Intake Medium Intake High Intake 
Dietary Variable n=138 n=138 n=138 
Carbohydrate (g/day) 199 234 273 
Total Sugars (g/day) 79 110 143 
Natural Sugars (g/day) 32 59 90 
Added Sugars (g/day) 26 48 70 
Glycemic Index 49 53 56 
Glycemic Load 102 123 145 
Starch (servings/day) 1.1 2.1 3.4 
Simple Carbs 
(servings/day) 
1.3 2.7 4.4 
Protein (g/day) 63 77 92 
Total Fat (g/day) 60 72 85 
 Post-treatment (n=265) 
 Low Intake Medium Intake High Intake 
Dietary Variable n=88 n=88 n=88 
Carbohydrate (g/day) 189 216 251 
Total Sugars (g/day) 75 99 134 
Natural Sugars (g/day) 26 43 62 
Added Sugars (g/day) 30 50 83 
Glycemic Index 48 52 56 
Glycemic Load 95 113 134 
Starch (servings/day) 0.9 1.9 3.4 
Simple Carbs 
(servings/day) 
1.0 2.2 3.7 
Protein (g/day) 60 72 86 
Total Fat (g/day) 55 67 81 
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t 28 Supplementary Table 2. Unadjusted  time-to-event cox proportional hazards analysis for all-cause mortality and recurrence by dietary intake 
Pretreatment Intake 
Low Medium High Ptrend 
n=138 n=138 n=138 
Mortality 
Carbohydrate 1.0 1.26 (0.67, 2.36) 1.78 (0.98, 3.22) 0.05* 
Total Sugar 1.0 0.94 (0.51, 1.73) 1.44 (0.81, 2.54) 0.18* 
Added Sugar 1.0 1.28 (0.67, 2.45) 1.22 (0.63, 2.35) 0.58 
Natural Sugar 1.0 0.83 (0.43, 1.58) 0.93 (0.50, 1.74) 0.19 
Glycemic Index 1.0 1.18 (0.67, 2.09) 0.95 (0.52, 1.71) 0.65 
Glycemic Load 1.0 1.12 (0.59, 2.11) 1.70 (0.94, 3.10) 0.06* 
Starchy Foods  1.0 0.74 (0.43, 1.27) 0.47 (0.25, 0.86)* 0.01* 
Simple Carb Foods  1.0 1.75 (0.93, 3.28) 2.20 (1.17, 4.12)* 0.02* 
Protein  1.0 0.77 (0.44, 1.35) 0.74 (0.42, 1.32) 0.31 
Fat 1.0 0.73 (0.41, 1.30) 0.83 (0.48, 1.45) 0.51 
Recurrence 
Carbohydrate 1.0 0.83 (0.46, 1.48) 1.12 (0.65, 1.95) 0.64 
Total Sugar 1.0 0.92 (0.51, 1.66) 1.31 (0.75, 2.29) 0.32 
Added Sugar 1.0 1.47 (0.75, 2.89) 1.43 (0.72, 2.83) 0.34 
Natural Sugar 1.0 1.08 (0.58, 2.02) 0.82 (0.42, 1.60) 0.58 
Glycemic Index 1.0 1.35 (0.78, 2.36) 0.91 (0.50, 1.66) 0.73 
Glycemic Load 1.0 0.61 (0.33, 1.11) 1.02 (0.60, 1.75) 0.91 
Starchy Foods  1.0 0.84 (0.50, 1.43) 0.52 (0.28, 0.94)* 0.03* 
Simple Carb Foods  1.0 1.57 (0.87, 2.84) 1.64 (0.90, 2.99) 0.12 
Protein  1.0 0.66 (0.37, 1.17) 0.89 (0.37, 1.17) 0.70 
Fat 1.0 1.10 (0.61, 1.98) 1.32 (0.75, 2.33) 0.32 
Post-Treatment Intake 
Low Medium High Ptrend 
n=88 n=89 n=88 
Mortality 
Carbohydrate 1.0 0.81 (0.28, 2.33) 1.66 (0.69, 4.00) 0.20* 
Total Sugar 1.0 1.56 (0.63, 3.88) 0.94 (0.35, 2.53) 0.81 
Added Sugar 1.0 0.95 (0.25, 3.55) 3.44 (1.24, 9.58) 0.006* 
Natural Sugar 1.0 0.79 (0.29, 2.12) 0.78 (0.29, 2.09) 0.28 
Glycemic Index 1.0 1.10 (0.41, 2.96) 1.32 (0.51, 3.41) 0.14* 
Glycemic Load 1.0 1.12 (0.42, 2.98) 1.37 (0.55, 3.40) 0.50 
Starchy Foods  1.0 0.36 (0.13, 0.99)* 0.61 (0.26, 1.41) 0.29 
Simple Carb Foods  1.0 1.07 (0.45, 2.59) 0.92 (0.36, 2.35) 0.86 
Protein  1.0 0.70 (0.30, 1.63) 0.37 (0.13, 1.04) 0.06* 
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t 29 Carbohydrate 1.0 1.27 (0.53, 3.07) 2.42 (1.10, 5.31) 0.02* Total Sugar 1.0 1.02 (0.47, 2.21) 1.11 (0.52, 2.36) 0.78 
Added Sugar 1.0 2.17 (0.88, 5.39) 2.31 (0.94, 5.67) 0.10* 
Natural Sugar 1.0 1.26 (0.58, 2.73) 0.88 (0.38, 2.04) 0.78 
Glycemic Index 1.0 0.96 (0.47, 1.95) 0.59 (0.26, 1.30) 0.21 
Glycemic Load 1.0 1.27 (0.57, 2.84) 1.50 (0.70, 3.23) 0.30 
Starchy Foods  1.0 1.04 (0.30, 3.59)  1.42 (0.45, 4.47) 0.52 
Simple Carb Foods  1.0 1.02 (0.29, 3.51) 1.35 (0.43, 4.28) 0.58 
Protein  1.0 0.66 (0.32, 1.39) 0.60 (0.28, 1.29) 0.19* 
Fat 1.0 0.39 (0.17, 0.88)* 0.53 (0.26, 1.11) 0.08* 
*Denotes significance at P≤0.20 
   
a
N=199 participants included in analysis 
 
Page 29 of 30
John Wiley & Sons, Inc.
International Journal of Cancer













Low Medium High Ptrend 
Carbohydrate 1.0 0.64 (0.21, 1.98) 2.18 (0.78, 6.11) 0.11 
Total Sugar 1.0 1.44 (0.53, 3.91) 0.83 (0.29, 2.33) 0.61 
Added Sugar 1.0 1.33 (0.33, 5.35) 2.76 (0.92, 8.26) 0.06 
Natural Sugar 1.0 0.87 (0.30, 2.46) 0.88 (0.26, 2.97) 0.82 
Glycemic Index 1.0 1.28 (0.44, 3.75) 1.73 (0.59, 5.12) 0.32 
Glycemic Load 1.0 1.12 (0.39, 3.19) 1.66 (0.59, 4.72) 0.34 
Starchy Foods 1.0 0.45, 0.13, 1.60) 0.74 (0.21, 2.63) 0.78 
Simple Carb Foods 1.0 0.99 (0.39, 2.53) 0.65 (0.24, 1.75) 0.39 
Protein 1.0 1.10 (0.45, 2.73) 0.61 (0.20, 1.90) 0.43 




Carbohydrate 1.0 0.78 (0.20, 2.95) 1.52 (0.45, 5.20) 0.46 
Total Sugar 1.0 1.10 (0.31, 3.70) 0.60 (0.15, 2.48) 0.44 
Added Sugar 1.0 2.10 (0.38, 11.52) 1.37 (0.29, 6.38) 0.68 
Natural Sugar 1.0 0.99 (0.24, 3.98) 0.39 (0.08, 1.94) 0.24 
Glycemic Index 1.0 1.39 (0.34, 5.67) 2.58 (0.63, 10.56) 0.19 
Glycemic Load 1.0 1.81 (0.48, 6.81) 1.82 (0.52, 6.36) 0.36 
Starchy Foods 1.0 0.81 (0.17, 3.79) 1.01 (0.20, 5.12) 0.91) 
Simple Carb Foods 1.0 1.03 (0.26, 4.12) 1.47 (0.39, 5.49) 0.54 
Protein 1.0 1.07 (0.30, 3.85) 1.51 (0.40, 5.79) 0.54 
Fat 1.0 0.08 (0.01, 0.69)* 0.67 (0.21, 2.15) 0.97 
   a
Adjusted for age, tumor site, cancer stage, smoking, total fruit and vegetable intake, HPV-status, percent weight   
change and total caloric intake 
   b
N=199 participants included in analysis 
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